effect overlay
activetrials
Stroke
Stroke
AXANA 0.1: Portable MRI Study

Feasibility assessment of the Wellumio ‘Axana’ 0.1T portable magnetic resonance imaging device The ‘Portable MRI study’

HREC: 2024.072
Principal Investigator: Prof Bruce Campbell
Coordinator contact:
Funding: Commercial
Stroke
Stroke
RAISE

A multicenter, double-blinded, placebo-controlled, single ascending dose, two-part, randomized, phase 2 clinical trial to assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BB-031 in acute ischemic stroke (AIS) patients

HREC: 2024.068
Principal Investigator: Prof Bruce Campbell
Coordinator contact:
Funding: Commercial
Active Trials - Other
Peripheral Neuropathy
Argenx BV

A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy (MMN)

HREC: 2024.051
Principal Investigator: Dr Belinda Cruse
Coordinator contact: Callum Hollis
Funding: Commercial
Dementia
Dementia
XanaMIA

A Phase 2b, Double-Blind, Placebo-Controlled, Parallel-Groups, 36-Week, 2-Arm Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg daily in Patients with Mild or Moderate Dementia due to Alzheimer's Disease

HREC: 2024.032
Principal Investigator: A/Prof David Darby
Coordinator contact: Lesley-Anne Attard
Funding: Commercial
Active Trials - Other
Neurophysiology
Myasthenia Gravis Health Economic Modelling

An investigator-initiated national prospective health economics study to optimise the use of immunoglobulin treatment in adults with Myasthenia Gravis

HREC: 2024.022
Principal Investigator: Dr Belinda Cruse
Coordinator contact:
Funding: Non-Commercial